☰

Srividya Swaminathan, Ph.D. - Publications

Affiliations: 
2013 Genetic, Molecular, and Cell Biology University of Southern California, Los Angeles, CA, United States 
Area:
Immunology, Molecular Biology, Cell Biology
Tree Info Grants Similar researchers PubMed Report error

42 high-probability publications. We are testing a new system for linking publications to authors. You can help! If you notice any inaccuracies, please sign in and mark papers as correct or incorrect matches. If you identify any major omissions or other inaccuracies in the publication list, please let us know.

Year Citation  Score
2023 Li Y, Xue M, Deng X, Dong L, Nguyen LXT, Ren L, Han L, Li C, Xue J, Zhao Z, Li W, Qing Y, Shen C, Tan B, Chen Z, ... ... Swaminathan S, et al. TET2-mediated mRNA demethylation regulates leukemia stem cell homing and self-renewal. Cell Stem Cell. 30: 1072-1090.e10. PMID 37541212 DOI: 10.1016/j.stem.2023.07.001  0.306
2023 Kumar A, Taghi Khani A, Duault C, Aramburo S, Sanchez Ortiz A, Lee SJ, Chan A, McDonald T, Huang M, Lacayo NJ, Sakamoto KM, Yu J, Hurtz C, Carroll M, Tasian SK, ... ... Swaminathan S, et al. Intrinsic suppression of type I interferon production underlies the therapeutic efficacy of IL-15-producing natural killer cells in B-cell acute lymphoblastic leukemia. Journal For Immunotherapy of Cancer. 11. PMID 37217248 DOI: 10.1136/jitc-2022-006649  0.443
2023 Taghi Khani A, Kumar A, Sanchez Ortiz A, Radecki KC, Aramburo S, Lee SJ, Hu Z, Damirchi B, Lorenson MY, Wu X, Gu Z, Stohl W, Sanz I, Meffre E, Müschen M, ... ... Swaminathan S, et al. Isoform-specific knockdown of long and intermediate prolactin receptors interferes with evolution of B-cell neoplasms. Communications Biology. 6: 295. PMID 36941341 DOI: 10.1038/s42003-023-04667-8  0.707
2022 Cluff E, Magdaleno CC, Fernandez E, House T, Swaminathan S, Varadaraj A, Rajasekaran N. Hypoxia-inducible factor-1 alpha expression is induced by IL-2 via the PI3K/mTOR pathway in hypoxic NK cells and supports effector functions in NKL cells and ex vivo expanded NK cells. Cancer Immunology, Immunotherapy : Cii. PMID 34999917 DOI: 10.1007/s00262-021-03126-9  0.342
2021 Kumar A, Lee SJ, Liu Q, Chan AKN, Pokharel SP, Yu J, Chen CW, Swaminathan S. Generation and validation of CRISPR-engineered human natural killer cell lines for research and therapeutic applications. Star Protocols. 2: 100874. PMID 34746857 DOI: 10.1016/j.xpro.2021.100874  0.321
2021 Duault C, Kumar A, Taghi Khani A, Lee SJ, Yang L, Huang M, Hurtz C, Manning B, Ghoda LY, McDonald T, Lacayo NJ, Sakamoto KM, Carroll MP, Tasian SK, Marcucci G, ... ... Swaminathan S, et al. Activated Natural Killer Cells Predict Poor Clinical Prognosis in High-risk B- and T- cell Acute Lymphoblastic Leukemia. Blood. PMID 34077953 DOI: 10.1182/blood.2020009871  0.407
2020 Swaminathan S, Hansen AS, Heftdal LD, Dhanasekaran R, Deutzmann A, Fernandez WDM, Liefwalker DF, Horton C, Mosley A, Liebersbach M, Maecker HT, Felsher DW. MYC functions as a switch for natural killer cell-mediated immune surveillance of lymphoid malignancies. Nature Communications. 11: 2860. PMID 32503978 DOI: 10.1038/S41467-020-16447-7  0.483
2020 Hurtz C, Carroll MP, Tasian SK, Wertheim G, Bhansali RS, Lee SJ, Kumar A, Lehman A, Loftus JP, Jeschke G, Crispino JD, Besson T, Shi J, Swaminathan S. DYRK1A Is Required to Alleviate Replication Stress in KMT2A-Rearranged Acute Lymphoblastic Leukemia Blood. 136: 39-40. DOI: 10.1182/BLOOD-2020-141258  0.432
2020 Duault C, Kumar A, Taghi Khani A, Lee SJ, Yang L, Huang M, Hurtz C, Manning B, Ghoda L, McDonald T, Lacayo NJ, Sakamoto KM, Carroll MP, Marcucci G, Yu J, ... ... Swaminathan S, et al. Activated Natural Killer Cells Are Associated with Poor Clinical Prognosis in High-Risk B- and T- Cell Acute Lymphoblastic Leukemia Blood. 136: 39-39. DOI: 10.1182/blood-2020-140044  0.423
2019 Swaminathan S, Heftdal LD, Liefwalker D, Dhanasekaran R, Deutzmann A, Horton C, Mosley A, Liebersbach M, Gentles A, Maecker HT, Felsher D. MYC Oncogene Abrogates Natural Killer (NK) Cell-Mediated Immune Surveillance of B- and T- Lymphoid Malignancies By Suppressing STAT1/2-Type I IFN Signaling Blood. 134: 730-730. DOI: 10.1182/Blood-2019-122607  0.368
2018 Lai I, Swaminathan S, Baylot V, Mosley A, Dhanasekaran R, Gabay M, Felsher DW. Lipid nanoparticles that deliver IL-12 messenger RNA suppress tumorigenesis in MYC oncogene-driven hepatocellular carcinoma. Journal For Immunotherapy of Cancer. 6: 125. PMID 30458889 DOI: 10.1186/S40425-018-0431-X  0.307
2018 Swaminathan S, Heftdal LD, Liefwalker DF, Dhanasekaran R, Deutzmann A, Horton C, Mosley A, Liebersbach M, Maecker HT, Felsher D. MYC Functions As a Master Switch for Natural Killer Cell-Mediated Immune Surveillance of Lymphoid Malignancies Blood. 132: 2619-2619. DOI: 10.1182/Blood-2018-99-110472  0.364
2018 Heftdal LD, Swaminathan S, Felsher DW. Abstract 126: MYC-driven lymphomas suppress NK surveillance by blocking maturation of early NK cells Tumor Biology. DOI: 10.1158/1538-7445.Am2018-126  0.301
2015 Swaminathan S, Müschen M. Infectious origins of childhood leukemia. Oncotarget. 6: 16798-9. PMID 26196452 DOI: 10.18632/Oncotarget.4630  0.731
2015 Shojaee S, Caeser R, Buchner M, Park E, Swaminathan S, Hurtz C, Geng H, Chan LN, Klemm L, Hofmann WK, Qiu YH, Zhang N, Coombes KR, Paietta E, Molkentin J, et al. Erk Negative Feedback Control Enables Pre-B Cell Transformation and Represents a Therapeutic Target in Acute Lymphoblastic Leukemia. Cancer Cell. 28: 114-28. PMID 26073130 DOI: 10.1016/J.Ccell.2015.05.008  0.783
2015 Swaminathan S, Klemm L, Park E, Papaemmanuil E, Ford A, Kweon SM, Trageser D, Hasselfeld B, Henke N, Mooster J, Geng H, Schwarz K, Kogan SC, Casellas R, Schatz DG, et al. Mechanisms of clonal evolution in childhood acute lymphoblastic leukemia. Nature Immunology. 16: 766-74. PMID 25985233 DOI: 10.1038/Ni.3160  0.589
2015 Buchner M, Swaminathan S, Chen Z, Müschen M. Mechanisms of pre-B-cell receptor checkpoint control and its oncogenic subversion in acute lymphoblastic leukemia. Immunological Reviews. 263: 192-209. PMID 25510278 DOI: 10.1111/Imr.12235  0.695
2015 Klemm L, Swaminathan S, Papaemmanuil E, Ford AM, Greaves M, Casellas R, Schatz D, Lieber MR, Muschen M. Exposure to Inflammatory Immune Responses As Driver of Clonal Evolution in Childhood Acute Lymphoblastic Leukemia Blood. 126: 166-166. DOI: 10.1182/Blood.V126.23.166.166  0.712
2014 Swaminathan S, Müschen M. Follicular lymphoma: too many reminders for a memory B cell. The Journal of Clinical Investigation. 124: 5095-8. PMID 25384212 DOI: 10.1172/Jci79189  0.672
2014 Kharabi Masouleh B, Geng H, Hurtz C, Chan LN, Logan AC, Chang MS, Huang C, Swaminathan S, Sun H, Paietta E, Melnick AM, Koeffler P, Müschen M. Mechanistic rationale for targeting the unfolded protein response in pre-B acute lymphoblastic leukemia. Proceedings of the National Academy of Sciences of the United States of America. 111: E2219-28. PMID 24821775 DOI: 10.1073/Pnas.1400958111  0.646
2014 Swaminathan S, Duy C, Müschen M. BACH2-BCL6 balance regulates selection at the pre-B cell receptor checkpoint. Trends in Immunology. 35: 131-7. PMID 24332591 DOI: 10.1016/J.It.2013.11.002  0.619
2014 Gang EJ, Hsieh YT, Pham J, Zhao Y, Nguyen C, Huantes S, Park E, Naing K, Klemm L, Swaminathan S, Conway EM, Pelus LM, Crispino J, Mullighan CG, McMillan M, et al. Small-molecule inhibition of CBP/catenin interactions eliminates drug-resistant clones in acute lymphoblastic leukemia. Oncogene. 33: 2169-78. PMID 23728349 DOI: 10.1038/Onc.2013.169  0.462
2014 Swaminathan S, Klemm L, Park E, Ford AM, Kweon S, Trageser D, Hasselfeld B, Henke N, Geng H, Schwarz K, Casellas R, Schatz DG, Lieber MR, Papaemmanuil E, Greaves M, et al. Mechanisms of Clonal Evolution of Pre-Leukemic Clones in Childhood Pre-B Acute Lymphoblastic Leukemia Blood. 124: 861-861. DOI: 10.1182/Blood.V124.21.861.861  0.725
2014 Park E, Swaminathan S, Sadiyah MF, Igarashi K, Melnick A, Muschen M. BACH2 promotes Lineage-Specific Fate Decisions in BCR-ABL1-Driven Leukemia Blood. 124: 513-513. DOI: 10.1182/Blood.V124.21.513.513  0.707
2014 Lee J, Buchner M, Geng H, Swaminathan S, Park E, Park A, Lin-Chao S, So CW, Muschen M. The Linker Protein GAS7 Negatively Regulates Pre-B Cell Differentiation and Amplifies Proliferation and Survival Signals in Acute Lymphoblastic Leukemia Blood. 124: 3777-3777. DOI: 10.1182/Blood.V124.21.3777.3777  0.774
2013 Swaminathan S, Huang C, Geng H, Chen Z, Harvey R, Kang H, Ng C, Titz B, Hurtz C, Sadiyah MF, Nowak D, Thoennissen GB, Rand V, Graeber TG, Koeffler HP, et al. BACH2 mediates negative selection and p53-dependent tumor suppression at the pre-B cell receptor checkpoint. Nature Medicine. 19: 1014-22. PMID 23852341 DOI: 10.1038/Nm.3247  0.646
2013 Masouleh BK, Geng H, Hurtz C, Huang C, Chan LN, Swaminathan S, Sun H, Koeffler HP, Melnick A, Paietta E, Glimcher LH, Muschen M. The Plasma Cell Transcription Factor XBP1 is Required To Mitigate The Unfolded Protein Response In Ph+ ALL Blood. 122: 836-836. DOI: 10.1182/Blood.V122.21.836.836  0.71
2013 Buchner M, Geng H, Swaminathan S, Park E, Klemm L, Lin-Chao S, So CW, Muschen M. Gas7 Induces The Proliferation Of Ph+ ALL Cells and Prevents The Differentiation Of Early B Cell Progenitors Into CD25high Small Pre-B Cells Blood. 122: 2506-2506. DOI: 10.1182/Blood.V122.21.2506.2506  0.709
2012 Swaminathan S, Klemm L, Ford AM, Schwarz K, Casellas R, Hennighausen L, Geng H, Schatz DG, Lieber MR, Greaves M, Muschen M. Cooperation Between Aid and the Rag1/Rag2 V(D)J Recombinase Drives Clonal Evolution of Childhood Acute Lymphoblastic Leukemia Blood. 120: 519-519. DOI: 10.1182/Blood.V120.21.519.519  0.746
2012 Shojaee S, Buchner M, Swaminathan S, Geng H, Chan L, Bothe M, Chen Z, Melnick A, Molkentin J, Martin G, Koeffler HP, Muschen M. Negative Feedback Signaling Enables Leukemic Transformation by Oncogenic Tyrosine Kinases Blood. 120: 1352-1352. DOI: 10.1182/Blood.V120.21.1352.1352  0.733
2012 Swaminathan S, Kang H, Harvey RC, Huang C, Buchner M, Chen Z, Geng H, Hall A, Igarashi K, Carroll WL, Willman CL, Melnick A, Muschen M. BACH2 Is Required for Pre-B Cell Receptor Checkpoint Control and p53-Dependent Tumor Surveillance Blood. 120: 1300-1300. DOI: 10.1182/Blood.V120.21.1300.1300  0.743
2012 Shojaee S, Buchner M, Swaminathan S, Chan L, Bothe M, Geng H, Melnick A, Molkentin J, Martin G, Koeffler P, Muschen M. Abstract 2944: Targeting negative feedback signaling in tyrosine kinase-driven malignancies Cancer Research. 72: 2944-2944. DOI: 10.1158/1538-7445.Am2012-2944  0.684
2011 Duy C, Hurtz C, Shojaee S, Cerchietti L, Geng H, Swaminathan S, Klemm L, Kweon SM, Nahar R, Braig M, Park E, Kim YM, Hofmann WK, Herzog S, Jumaa H, et al. BCL6 enables Ph+ acute lymphoblastic leukaemia cells to survive BCR-ABL1 kinase inhibition. Nature. 473: 384-8. PMID 21593872 DOI: 10.1038/Nature09883  0.742
2011 Klemm L, Swaminathan S, Ford AM, Schwarz K, Schatz DG, Lieber MR, Greaves MF, Muschen M. Infectious Origins of Childhood Leukemia Blood. 118: 751-751. DOI: 10.1182/Blood.V118.21.751.751  0.751
2011 Swaminathan S, Huang C, Titz B, Buchner M, Geng H, Graeber TG, Willman CL, Igarashi K, Melnick A, Muschen M. BACH2 Mediates Early B Cell Differentiation and Oncogene-Induced Senescence in Acute Lymphoblastic Leukemia Blood. 118: 562-562. DOI: 10.1182/Blood.V118.21.562.562  0.748
2011 Gang EJ, Park E, Jayaprakash P, Huantes S, Hsieh Y, Hanami D, Swaminathan S, Klemm L, Mschen M, McMillan M, Nguyen C, Zhao Y, Kahn M, Kim Y. Abstract B218: CBP/catenin antagonism inhibits self-renewal of acute lymphoblastic leukemia. Molecular Cancer Therapeutics. 10. DOI: 10.1158/1535-7163.Targ-11-B218  0.509
2010 Duy C, Yu JJ, Nahar R, Swaminathan S, Kweon SM, Polo JM, Valls E, Klemm L, Shojaee S, Cerchietti L, Schuh W, Jäck HM, Hurtz C, Ramezani-Rad P, Herzog S, et al. BCL6 is critical for the development of a diverse primary B cell repertoire. The Journal of Experimental Medicine. 207: 1209-21. PMID 20498019 DOI: 10.1084/Jem.20091299  0.799
2010 Swaminathan S, Klemm L, Kweon S, Ford A, Schwarz K, Casellas R, Hennighausen L, Schatz DG, Lieber MR, Greaves MF, Muschen M. IL7Rα Signaling Prevents Premature Expression of AID In Human Pre-B Cells: Implications for Clonal Evolution of Childhood Leukemia Blood. 116: 26-26. DOI: 10.1182/Blood.V116.21.26.26  0.756
2009 Swaminathan S. Gamma-secretase inhibitors--do they have a role in the treatment of B cell lymphoma? Cancer Biology & Therapy. 8: 2144-6. PMID 20068386 DOI: 10.4161/cbt.8.22.10034  0.447
2009 Duy C, Yu JJ, Swaminathan S, Nahar RR, Kweon S, Polo JM, Valls E, Klemm L, Cerchietti L, Levetzow Gv, Herzog S, Jumaa H, Alborán IMd, Melnick A, Ye BH, et al. BCL6 Is Critical for the Development of a Diverse Primary B Cell Repertoire. Blood. 114: 91-91. DOI: 10.1182/Blood.V114.22.91.91  0.807
2009 Duy C, Cerchietti L, Yu JJ, Ci W, Swaminathan S, Nahar RR, Kweon S, Klemm L, Ye BH, Melnick A, Müschen M. BCL6-Dependent Negative Regulation of Cell Cycle Checkpoint Regulators Enables Drug-Resistance in Ph+ Acute Lymphoblastic Leukemia. Blood. 114: 765-765. DOI: 10.1182/Blood.V114.22.765.765  0.781
2009 Hurtz C, Duy C, Cerchietti L, Park E, Ci W, Swaminathan S, Kweon S, Klemm L, Kim Y, Martinelli G, Hofmann W, Ye BH, Melnick A, Müschen M. BCL6 Is Required for Leukemia-Initiation and Self-Renewal Signaling in Chronic Myeloid Leukemia. Blood. 114: 2167-2167. DOI: 10.1182/Blood.V114.22.2167.2167  0.717
Show low-probability matches.